

Resource Summary Report

Generated by SPARC SAWG on Sep 3, 2026

Alexa Fluor(R) 700 anti-mouse/human CD11b

RRID:AB_493705

Type: Antibody

Proper Citation

BioLegend Cat# 101222, RRID:AB_493705

Antibody Information

URL: http://antibodyregistry.org/AB_493705

Proper Citation: BioLegend Cat# 101222, RRID:AB_493705

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Alexa Fluor(R) 700 anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_493705

Vendor: BioLegend

Catalog Number: 101222

Record Creation Time: 20231110T044338+0000

Record Last Update: 20260829T222440+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 700 anti-mouse/human CD11b.

No alerts have been found for Alexa Fluor(R) 700 anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 98 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Lin SC, et al. (2026) MyD88 signaling in myeloid cells induces gastrointestinal tract injury and systemic inflammation after West Nile virus infection. Cell reports, 45(1), 116852.

Arumugam P, et al. (2026) Mitochondrial transfer to granulocytic myeloid-derived suppressor cells augments immunosuppressive activity. Cell reports, 45(3), 117057.

Li B, et al. (2026) Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy. Cell host & microbe, 34(4), 657.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Wang L, et al. (2026) The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Developmental cell, 61(6), 1208.

Maeda Y, et al. (2026) Mucosal innate immune activation as the trigger to Prevotella species-induced arthritis in genetically resistant mice. Cell reports, 45(1), 116755.

Caldwell BA, et al. (2026) Monocyte exhaustion associated with systemic lupus erythematosus. Autoimmunity, 59(1), 2674057.

Choi W, et al. (2026) Glycogen phosphorylase L confers metabolic flexibility in neutrophils to fight fungal infections in nutrient-deprived tissues. Cell host & microbe, 34(4), 692.

Stanbery AG, et al. (2026) Tuft cells promote reactivation of memory Th2 cells and are required for protective immunity to intestinal helminth re-infection. Immunity, 59(5), 1381.

Al Jawazneh A, et al. (2026) Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis. The Journal of experimental medicine, 223(7).

Lu G, et al. (2026) In vivo detection of immune responses via cytokine activity labeling. Cell.

Huang C, et al. (2026) Pregnenolone promotes immune evasion through blocking endogenous retrovirus expression. Cell metabolism, 38(5), 981.

Barainka M, et al. (2026) Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy. iScience, 29(2), 114597.

Yang Y, et al. (2026) Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8⁺ T cells. *Journal for immunotherapy of cancer*, 14(3).

Vurnek D, et al. (2026) Protocol for mapping murine myeloid bone marrow progenitors and their differentiation into CD103⁺ cDC1s and CD301b⁺ cDC2s. *STAR protocols*, 7(2), 104508.

Zhang L, et al. (2026) Bcl11a orchestrates multilineage integrity in aging hematopoiesis by regulating multipotent progenitor fate decisions. *Cell reports*, 45(7), 117716.

Castellano M, et al. (2025) Ribonuclease activity undermines immune sensing of naked extracellular RNA. *Cell genomics*, 5(5), 100874.

Schwartz L, et al. (2025) Obesity promotes urinary tract infection by disrupting bladder focal adhesion kinase signaling. *iScience*, 28(11), 113862.

Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. *Neoplasia (New York, N.Y.)*, 67, 101196.

Stockmann AP, et al. (2025) DF6215, an ??-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. *Cell reports. Medicine*, 102518.